The Safety and Efficacy of Roflumilast Foam in HS

NCT07263230

Status	RECRUITING
Phase	Phase 2
Sponsor	Beth Israel Deaconess Medical Center
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (10)

- Male or female subjects aged 18 years or older
- Participants are legally competent to sign and give informed consent.
- Diagnosis of HS based on clinical history and physical examination for at least 3 months.
- Diagnosis of HS (Hurley I or II) with a total AN count of at least 4 to d 10, with no draining tunnels at screening and baseline visits with an AN of \>4 affecting at least one distinct anatomical region.
- Agreement to NOT use topical and systemic antibiotics and intralesional steroids for treatment of HS during the study.

... and 5 more (see full listing online)

Exclusion (17)

- Subjects with any medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
- Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments (see table of Excluded Medications and Treatments with washout timelines).
- Presence of draining tunnels at screening or at baseline visits
- Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.
- Subjects with skin conditions other than HS that would interfere with evaluations of the effect of the study medication on HS, as determined by the Investigator.

... and 12 more (see full listing online)

Locations (1 total)

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States